Entries by Organicell

,

Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round

MIAMI, FL / ACCESSWIRE / August 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction. Organicell also closed on an additional $1.5 million of funding at $0.04 […]

ORGANICELL TEAM MEMBER JULIAN MILBERG’S “A CELL UNDERGOING ANAPHASE” WINS 2ND IN THE ISCT CELL & GENE THERAPY’S INSTA-YOUR-CELL PHOTO CHALLENGE

One of our team members, Julian Milberg’s image was featured on the front cover of the June 2021 issue of ISCT Cell & Gene Therapy Cytotherapy. His image “A cell undergoing anaphase” won 2nd place in the ISCT Cell & Gene Therapy’s Insta-Your-Cells 2020-2021 photo challenge. We are incredibly proud of his accomplishment.⁠ ⁠⁠⁠Anaphase is […]

Organicell Receives Approval in Pakistan for the use of Zofin™ for Compassionate Grounds for COVID-19

Clinical Trials To Commence Immediately Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. The Drug Regulatory Authority of Pakistan […]

Organicell Begins Up-Listing Process On NASDAQ Exchange

Miami, FL (May 4, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC. To qualify and be approved for such […]